Compare CARE & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | PEPG |
|---|---|---|
| Founded | 1974 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.9M | 440.0M |
| IPO Year | 2020 | 2022 |
| Metric | CARE | PEPG |
|---|---|---|
| Price | $20.56 | $5.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 156.8K | ★ 721.3K |
| Earning Date | 04-30-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.19 | 25.61 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $9.72 | N/A |
| P/E Ratio | $20.79 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $13.61 | $0.89 |
| 52 Week High | $22.51 | $7.80 |
| Indicator | CARE | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 47.02 |
| Support Level | $19.32 | $4.36 |
| Resistance Level | $21.46 | $6.81 |
| Average True Range (ATR) | 0.57 | 0.59 |
| MACD | -0.16 | -0.07 |
| Stochastic Oscillator | 21.21 | 35.87 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.